Printer Friendly

Printed from http://www.researchandmarkets.com/reports/2155230

Epidemiology: Breakthrough Cancer Pain – Explosion of Pain Due to Increased Cancer Incidence

Description:
This module gives an overview of breakthrough cancer pain in the seven major markets. In this module, Datamonitor provides an estimate and a 10-year forecast of prevalent cancer patients with breakthrough cancer pain.

Global cancer incidence is increasing rapidly, with about 12.4 million cases in 2008. In the next 50 years, cancer incidence will rise globally, driven by aging populations and an increase in risk factors. Consequently, the cancer burden will increase substantially across populations leading to increased mortality, disability, and unbearable pain, including breakthrough cancer pain.

Scope

- Gain insights into the estimates and forecast of breakthrough cancer pain in the US, Japan, France, Germany, Italy, Spain, and the UK.
- Gain insights into the possible underlying risk factors driving the epidemiology of cancer in the seven major markets.

Highlights

- Datamonitor estimates that there were 2.6 million cancer patients experiencing breakthrough pain in the seven major markets in 2011. In the US, there were around 1.03 million cancer patients with breakthrough cancer pain in 2011. By 2021, Datamonitor estimates that the number of cancer patients experiencing breakthrough pain will reach 1.3 million.

- In Japan, approximately 455,800 cancer patients had breakthrough pain in 2011, but the number is expected to increase to approximately 536,700 by the end of 2021.

- In the five major EU markets (France, Germany, Italy, Spain, and the UK), there were 1.12 million cancer patients experiencing breakthrough pain. Germany had the highest number of breakthrough cancer pain patients with Spain having the least, in line with cancer incidence found in these countries.

Reasons to Purchase

- What are the most robust sources for breakthrough cancer pain prevalence data?
- What is the current cancer patient population with breakthrough pain in the seven major markets?
- How will the breakthrough cancer pain patient population change over the next decade in the US, Japan, France, Germany, Italy, Spain, and the UK?
 
Contents:
OVERVIEW
- Catalyst
- Summary

EXECUTIVE SUMMARY
- Key points
- Key findings

DISEASE DEFINITION AND DIAGNOSIS CRITERIA
- A unanimous definition of breakthrough pain is lacking
- Subtypes of breakthrough cancer pain

GLOBAL VARIATION AND HISTORICAL TRENDS
- Prevalence varies widely between and within markets
- Cancer incidence rates predict breakthrough cancer pain

RISK FACTORS
- Reproductive factors
- Exogenous hormones
- - Oral contraceptives
- - Hormone replacement therapy

- Lifestyle factors
- - Obesity
- - Alcohol consumption
- - Physical activity
- - Diet
- - Tobacco smoking

- Socioeconomic factors
- Genetic predisposition

EPIDEMIOLOGIC FORECASTING OF BREAKTHROUGH CANCER PAIN
- Sources of epidemiologic data
- - Sources of cancer data
- - Sources of breakthrough cancer pain data
- - Data sources not used
- - Population denominators

- Description of methods
- - Statistical analysis

EPIDEMIOLOGIC RESULTS
- Estimated incident cases and future trends in cancer
- Estimated prevalent cases and future trends in breakthrough cancer pain

DISCUSSION
- US
- Japan
- Five major EU markets
- Strengths and weaknesses of Datamonitor's epidemiologic projections

BIBLIOGRAPHY
- Journal papers
- Websites

APPENDIX
- Module methodology

TABLES
Table: Subtypes of breakthrough cancer pain
Table: Epidemiologic studies of breakthrough cancer pain in the seven major markets
Table: Cancer registry data sources from the seven major markets
Table: Sources of breakthrough cancer pain epidemiologic data used in this analysis
Table: Incident cancer cases in the seven major markets (000s), 2011â-21
Table: Breakthrough cancer pain prevalent cases in the seven major markets (000s), 2011â-21

FIGURES
Figure: Age-standardized male incidence rates of all cancers (except non-melanoma skin) in the seven major markets, 1975â-2002
Figure: Age-standardized female incidence rates of all cancers (except non-melanoma skin) in the seven major markets, 1975â-2002
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/2155230

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Tuesday, June 18, 2013
10:41:14 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Epidemiology: Breakthrough Cancer Pain – Explosion of Pain Due to Increased Cancer Incidence

Web Address

http://www.researchandmarkets.com/reports/2155230

Office Code

OC8DIQQMUMNXWY

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User EUR 4,360
Electronic (PDF) - Enterprisewide EUR 10,899

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Tuesday, June 18, 2013
10:41:14 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)